A PK/PD study comparing twice-daily to once-daily dosing regimens of ertugliflozin in healthy subjects

Objective: Ertugliflozin is approved in the US and European Union as a stand-alone product for adults with type 2 diabetes mellitus as once daily (QD) dosing. The approved fixed-dose combination (FDC) of ertugliflozin and immediate-release metformin is dosed twice daily (BID). This study assessed st...

Descripción completa

Detalles Bibliográficos
Autores principales: Dawra, Vikas Kumar, Liang, Yali, Shi, Haihong, Bass, Almasa, Hickman, Anne, Terra, Steven G., Zhou, Susan, Cutler, David, Sahasrabudhe, Vaishali
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dustri-Verlag Dr. Karl Feistle 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6528385/
https://www.ncbi.nlm.nih.gov/pubmed/30802200
http://dx.doi.org/10.5414/CP203343

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6528385/
https://www.ncbi.nlm.nih.gov/pubmed/30802200
http://dx.doi.org/10.5414/CP203343

Ejemplares similares